The registration of generic topical corticosteroid formulations in South Africa: a report
- Haigh, John M, Smith, Eric W
- Authors: Haigh, John M , Smith, Eric W
- Date: 2002
- Language: English
- Type: Article
- Identifier: vital:6368 , http://hdl.handle.net/10962/d1006068
- Description: [From the text]Topical corticosteroid formulations are used widely for a variety of skin conditions such as psoriasis and eczema. The most commonly used formulation types are cream, ointment, lotion and scalp application, with some mousse formulations being released recently onto the market for scalp application. The type of formulation used depends on the condition being treated. Dry lesions are normally treated with ointments and wet lesions with creams. Cosmetically, cream formulations are more acceptable as they can be rubbed in, thus leaving no residual oiliness. Scalp applications have to be less viscous to allow the formulation to pass through the hair and contact the scalp. Occlusion with plastic wrapping hydrates the stratum corneum and facilitates the passage of the corticosteroid through this barrier to the basal layer where the therapeutic effect is required.
- Full Text:
- Date Issued: 2002
- Authors: Haigh, John M , Smith, Eric W
- Date: 2002
- Language: English
- Type: Article
- Identifier: vital:6368 , http://hdl.handle.net/10962/d1006068
- Description: [From the text]Topical corticosteroid formulations are used widely for a variety of skin conditions such as psoriasis and eczema. The most commonly used formulation types are cream, ointment, lotion and scalp application, with some mousse formulations being released recently onto the market for scalp application. The type of formulation used depends on the condition being treated. Dry lesions are normally treated with ointments and wet lesions with creams. Cosmetically, cream formulations are more acceptable as they can be rubbed in, thus leaving no residual oiliness. Scalp applications have to be less viscous to allow the formulation to pass through the hair and contact the scalp. Occlusion with plastic wrapping hydrates the stratum corneum and facilitates the passage of the corticosteroid through this barrier to the basal layer where the therapeutic effect is required.
- Full Text:
- Date Issued: 2002
Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioeqivalence testing [authors' reply in Letters to the Editor]
- Smith, Eric W, Walker, Roderick B, Haigh, John M, Kanfer, Isadore
- Authors: Smith, Eric W , Walker, Roderick B , Haigh, John M , Kanfer, Isadore
- Date: 1998
- Language: English
- Type: text , Article
- Identifier: vital:6423 , http://hdl.handle.net/10962/d1006558
- Description: Reply to: Letter to the Editor by Singh GJ; Fleischer N; Lesko L; Williams R - relating to original article in Pharmaceutical Research (USA), Mar 1997, vol. 14, pp. 303-308.
- Full Text: false
- Date Issued: 1998
- Authors: Smith, Eric W , Walker, Roderick B , Haigh, John M , Kanfer, Isadore
- Date: 1998
- Language: English
- Type: text , Article
- Identifier: vital:6423 , http://hdl.handle.net/10962/d1006558
- Description: Reply to: Letter to the Editor by Singh GJ; Fleischer N; Lesko L; Williams R - relating to original article in Pharmaceutical Research (USA), Mar 1997, vol. 14, pp. 303-308.
- Full Text: false
- Date Issued: 1998
In vitro release of propranolol hydrochloride from topical vehicles
- Smith, Eric W, Haigh, John M
- Authors: Smith, Eric W , Haigh, John M
- Date: 1994
- Language: English
- Type: text , Article
- Identifier: vital:6435 , http://hdl.handle.net/10962/d1006612
- Description: Transdermal drug delivery is becoming increasingly important and for this reason it is clear that academia must ensure that current graduates are knowledgeable in all facets of topical drug administration. An in vitro diffusion cell experiment was designed to demonstrate the rate of release of propranolol hydrochloride (PHC) from three different topical vehicles: (i) an oil-in-water cream; (ii) a gel; and (iii) anointment. This experiment was performed by final-year students enroled in an undergraduate course on percutaneous absorption. In vitro release of PHC from the three bases to an aqueous receptor phase through silicone membrane was monitored spectrophotometrically at a wavelength of 290 nm. By monitoring and attempting to explain the numerous possible reasons for the different rates of drug release from the three vehicles, it was hoped that the students would gain a better understanding of the complexities of transdermal drug administration. Overall, the experiment would appear to be a good model for student investigation into factors affecting the release of drugs from topical formulations.
- Full Text:
- Date Issued: 1994
- Authors: Smith, Eric W , Haigh, John M
- Date: 1994
- Language: English
- Type: text , Article
- Identifier: vital:6435 , http://hdl.handle.net/10962/d1006612
- Description: Transdermal drug delivery is becoming increasingly important and for this reason it is clear that academia must ensure that current graduates are knowledgeable in all facets of topical drug administration. An in vitro diffusion cell experiment was designed to demonstrate the rate of release of propranolol hydrochloride (PHC) from three different topical vehicles: (i) an oil-in-water cream; (ii) a gel; and (iii) anointment. This experiment was performed by final-year students enroled in an undergraduate course on percutaneous absorption. In vitro release of PHC from the three bases to an aqueous receptor phase through silicone membrane was monitored spectrophotometrically at a wavelength of 290 nm. By monitoring and attempting to explain the numerous possible reasons for the different rates of drug release from the three vehicles, it was hoped that the students would gain a better understanding of the complexities of transdermal drug administration. Overall, the experiment would appear to be a good model for student investigation into factors affecting the release of drugs from topical formulations.
- Full Text:
- Date Issued: 1994
The human skin-blanching assay for comparing topical corticosteroid availability
- Smith, Eric W, Meyer, Eric, Haigh, John M, Maibach, Harold I
- Authors: Smith, Eric W , Meyer, Eric , Haigh, John M , Maibach, Harold I
- Date: 1991
- Language: English
- Type: Article
- Identifier: vital:6433 , http://hdl.handle.net/10962/d1006604
- Description: The human skin blanching assay remains in widespread use as a reliable, qualitative, comparative indicator of topical corticosteroid availability and potency. The experimental refinements promulgated by certain researchers in this field have yielded a versatile bioassay for the accurate assessment of new drugs or delivery vehicles. With the increasing appearance of generic topical corticosteroid formulations which compete with trade-name equivalents, the vital importance of this assay in regulatory affairs and assessing bioequivalence has been re-emphasized. It is stressed that if the blanching assay is to be used in this sphere, then multiple-reading trials must be conducted; important registration or clinical decisions cannot be made with any validity from short-term assessments.
- Full Text:
- Date Issued: 1991
- Authors: Smith, Eric W , Meyer, Eric , Haigh, John M , Maibach, Harold I
- Date: 1991
- Language: English
- Type: Article
- Identifier: vital:6433 , http://hdl.handle.net/10962/d1006604
- Description: The human skin blanching assay remains in widespread use as a reliable, qualitative, comparative indicator of topical corticosteroid availability and potency. The experimental refinements promulgated by certain researchers in this field have yielded a versatile bioassay for the accurate assessment of new drugs or delivery vehicles. With the increasing appearance of generic topical corticosteroid formulations which compete with trade-name equivalents, the vital importance of this assay in regulatory affairs and assessing bioequivalence has been re-emphasized. It is stressed that if the blanching assay is to be used in this sphere, then multiple-reading trials must be conducted; important registration or clinical decisions cannot be made with any validity from short-term assessments.
- Full Text:
- Date Issued: 1991
Blanching activities of betamethasone 17-valerate formulations: effect of the dosage form on topical drug availability
- Smith, Eric W, Meyer, Eric, Haigh, John M
- Authors: Smith, Eric W , Meyer, Eric , Haigh, John M
- Date: 1990
- Language: English
- Type: Article
- Identifier: vital:6432 , http://hdl.handle.net/10962/d1006602
- Description: The blanching activities of Betnovate© cream, lotion, ointment and scalp application (each containing 0.1 % betamethasone (as the 17-valerate)) were determined using healthy human subjects over a 32 h period in both the occludedand unoccluded modes. Considering that allfour formulation types contained the same label concentration of corticosteroid,it may bepresumed that theformulations would show similar topical drug availability: this was, however, not found to be the case. The scalp application demonstrated the highest topical availability in both the occluded and unoccluded modes. The lotion formulation showed the greatest increase in topical availability on occlusion and the ointment formulation was the least sensitive to the effects of occlusion. These differences, due solely to the effects of the vehicle, may have important clinical implications.
- Full Text:
- Date Issued: 1990
- Authors: Smith, Eric W , Meyer, Eric , Haigh, John M
- Date: 1990
- Language: English
- Type: Article
- Identifier: vital:6432 , http://hdl.handle.net/10962/d1006602
- Description: The blanching activities of Betnovate© cream, lotion, ointment and scalp application (each containing 0.1 % betamethasone (as the 17-valerate)) were determined using healthy human subjects over a 32 h period in both the occludedand unoccluded modes. Considering that allfour formulation types contained the same label concentration of corticosteroid,it may bepresumed that theformulations would show similar topical drug availability: this was, however, not found to be the case. The scalp application demonstrated the highest topical availability in both the occluded and unoccluded modes. The lotion formulation showed the greatest increase in topical availability on occlusion and the ointment formulation was the least sensitive to the effects of occlusion. These differences, due solely to the effects of the vehicle, may have important clinical implications.
- Full Text:
- Date Issued: 1990
Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilizing the human skin-blanching assay
- Meyer, Eric, Smith, Eric W, Haigh, John M, Kanfer, Isadore
- Authors: Meyer, Eric , Smith, Eric W , Haigh, John M , Kanfer, Isadore
- Date: 1988
- Language: English
- Type: Article
- Identifier: vital:6400 , http://hdl.handle.net/10962/d1006327
- Description: The human blanching assay was used to assess the potency of two new proprietary corticosteroid creams. The blanching abilities of 0.1% desonide cream and 0.05% halometasone cream were evaluated relative to the blanching elicited by 0.05% clobetasol 17-propionate cream, 0.1% betamethasone 17-valerate cream and 0.05% clobetasone 17-butyrate cream. The results of the trial indicated that the 0.1% desonide cream falls into the potent group of topical corticosteroid preparations and the 0.05% halomethasone cream falls into the moderately potent group.
- Full Text:
- Date Issued: 1988
- Authors: Meyer, Eric , Smith, Eric W , Haigh, John M , Kanfer, Isadore
- Date: 1988
- Language: English
- Type: Article
- Identifier: vital:6400 , http://hdl.handle.net/10962/d1006327
- Description: The human blanching assay was used to assess the potency of two new proprietary corticosteroid creams. The blanching abilities of 0.1% desonide cream and 0.05% halometasone cream were evaluated relative to the blanching elicited by 0.05% clobetasol 17-propionate cream, 0.1% betamethasone 17-valerate cream and 0.05% clobetasone 17-butyrate cream. The results of the trial indicated that the 0.1% desonide cream falls into the potent group of topical corticosteroid preparations and the 0.05% halomethasone cream falls into the moderately potent group.
- Full Text:
- Date Issued: 1988
- «
- ‹
- 1
- ›
- »